Prevalence and therapy of vascular risk factors in hospitalized type 2 diabetic patients

Published on Dec 23, 2000in Schweizerische Medizinische Wochenschrift
Henzen C1
Estimated H-index: 1
,
Hodel T1
Estimated H-index: 1
+ 3 AuthorsJoss R1
Estimated H-index: 1
Source
Abstract
: Type 2 diabetes mellitus is often associated with other risk factors for atherosclerotic disease, resulting in a marked increase in cardiovascular events and deaths. Combined treatment of hyperglycaemia, dyslipidaemia and hypertension significantly decreases the frequency and severity of diabetic microvascular and macrovascular complications. In a prospective cohort study including 356 type 2 diabetic patients (= 14% of all in-patients during a 6 months' period) the prevalence and treatment of cardiovascular risk factors were determined. Hypertension was diagnosed in 54% of the diabetic patients, albuminuria in 53% and dyslipidaemia in 47%; there were 40 smokers (17%). On admission the mean HbA1c was 7.7 +/- 2.0%, the mean fasting plasma glucose 10.0 +/- 4.2 mmol/l (and 8.9 +/- 3.9 mmol/l, p = 0.03, when discharged), the mean systolic blood pressure was 144 +/- 28 mm Hg (and 131 +/- 20, p < 0.0001, when discharged), and the triglycerides were 2.6 +/- 0.4 mmol/l. 34% of the hypertensive diabetic patients were treated with a combination of anti-hypertensive drugs, 44% of the dyslipidaemic diabetic patients were treated with statins, and 58% of all diabetic patients received aspirin or oral anticoagulation. 23% of the diabetic patients were treated by diet alone, 36% with insulin, 25% with sulfonylureas and 5% with metformin, while 11% were given a combination of antihyperglycaemic medication. In-hospital mortality was 11%. The diabetic patients were discharged on 2.9 +/- 1.7 different drugs. The prevalence of associated cardiovascular risk factors is high in type 2 diabetic patients, and thus a combination of drugs is often warranted. The rate of admissions and in-hospital mortality is high in type 2 diabetic patients.
References0
Newest
Cited By2
Newest
#1Michael BrändleH-Index: 27
#2G GoodallH-Index: 10
Last. William J. ValentineH-Index: 32
view all 5 authors...
Objectives: To evaluate the cost-effectiveness of pioglitazone versus placebo, given in addition to existing treatment regimens, in patients with type 2 diabetes and evidence of macrovascular disease in Switzerland. Methods: Event rates corresponding to macrovascular outcomes from the PROactive (Prospective Pioglitazone Clinical Trial in Macrovascular Events) trial of pioglitazone were used to project long-term clinical outcomes as part of a modified version of the previously validated CORE Diab...
13 CitationsSource
#2Peter GremingerH-Index: 1
Last. Paolo Ferrari (UWA: University of Western Australia)H-Index: 55
view all 5 authors...
The prevalence of hypertension in type 2 diabetics is high, though there is no published data for Switzerland. This prospective cohort survey determined the frequency of type 2 diabetes mellitus associated with hypertension from medical practitioners in Switzerland, and collected data on the diagnostic and therapeutic work‐up for cardiovascular risk patients. The Swiss Hypertension And Risk Factor Program (SHARP) is a two‐part survey: The first part, I‐SHARP, was a survey among 1040 Swiss physic...
32 CitationsSource